NASDAQ:ATHX

Athersys Competitors

$1.78
-0.13 (-6.81 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.77
Now: $1.78
$1.90
50-Day Range
$1.61
MA: $1.94
$2.37
52-Week Range
$1.53
Now: $1.78
$3.59
Volume1.66 million shs
Average Volume3.15 million shs
Market Capitalization$383.14 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.54

Competitors

Athersys (NASDAQ:ATHX) Vs. KRON, QURE, HRTX, IMGN, ACRS, and ATBPD

Should you be buying ATHX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Athersys, including Kronos Bio (KRON), uniQure (QURE), Heron Therapeutics (HRTX), ImmunoGen (IMGN), Aclaris Therapeutics (ACRS), and Antibe Therapeutics (ATBPD).

Kronos Bio (NASDAQ:KRON) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kronos Bio and Athersys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kronos Bio00403.00
Athersys00403.00

Kronos Bio currently has a consensus target price of $43.6667, indicating a potential upside of 60.07%. Athersys has a consensus target price of $9.00, indicating a potential upside of 405.62%. Given Athersys' higher possible upside, analysts plainly believe Athersys is more favorable than Kronos Bio.

Valuation & Earnings

This table compares Kronos Bio and Athersys' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kronos BioN/AN/AN/AN/AN/A
Athersys$5.63 million68.05$-44,580,000.00($0.29)-6.14

Kronos Bio has higher earnings, but lower revenue than Athersys.

Profitability

This table compares Kronos Bio and Athersys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kronos BioN/AN/AN/A
AthersysN/A-176.56%-112.67%

Institutional & Insider Ownership

27.9% of Athersys shares are owned by institutional investors. 12.6% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Athersys beats Kronos Bio on 4 of the 6 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for uniQure and Athersys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
uniQure011113.00
Athersys00403.00

uniQure currently has a consensus target price of $68.4615, indicating a potential upside of 102.91%. Athersys has a consensus target price of $9.00, indicating a potential upside of 405.62%. Given Athersys' higher possible upside, analysts plainly believe Athersys is more favorable than uniQure.

Volatility & Risk

uniQure has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Athersys has a beta of -1.54, indicating that its share price is 254% less volatile than the S&P 500.

Valuation & Earnings

This table compares uniQure and Athersys' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$7.28 million208.53$-124,200,000.00($3.11)-10.85
Athersys$5.63 million68.05$-44,580,000.00($0.29)-6.14

Athersys has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares uniQure and Athersys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
uniQure-2,738.33%-59.64%-41.47%
AthersysN/A-176.56%-112.67%

Institutional & Insider Ownership

78.3% of uniQure shares are owned by institutional investors. Comparatively, 27.9% of Athersys shares are owned by institutional investors. 2.8% of uniQure shares are owned by company insiders. Comparatively, 12.6% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

uniQure beats Athersys on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Heron Therapeutics and Athersys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01502.83
Athersys00403.00

Heron Therapeutics currently has a consensus target price of $29.60, indicating a potential upside of 78.31%. Athersys has a consensus target price of $9.00, indicating a potential upside of 405.62%. Given Athersys' stronger consensus rating and higher possible upside, analysts plainly believe Athersys is more favorable than Heron Therapeutics.

Volatility & Risk

Heron Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Athersys has a beta of -1.54, indicating that its share price is 254% less volatile than the S&P 500.

Valuation & Earnings

This table compares Heron Therapeutics and Athersys' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million10.39$-204,750,000.00($2.50)-6.64
Athersys$5.63 million68.05$-44,580,000.00($0.29)-6.14

Athersys has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Heron Therapeutics and Athersys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
AthersysN/A-176.56%-112.67%

Institutional & Insider Ownership

99.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Athersys shares are owned by institutional investors. 12.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ImmunoGen (NASDAQ:IMGN) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Athersys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Athersys00403.00

ImmunoGen currently has a consensus target price of $10.10, indicating a potential upside of 33.60%. Athersys has a consensus target price of $9.00, indicating a potential upside of 405.62%. Given Athersys' stronger consensus rating and higher possible upside, analysts plainly believe Athersys is more favorable than ImmunoGen.

Volatility & Risk

ImmunoGen has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Athersys has a beta of -1.54, indicating that its share price is 254% less volatile than the S&P 500.

Valuation & Earnings

This table compares ImmunoGen and Athersys' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million18.35$-104,130,000.00($0.70)-10.80
Athersys$5.63 million68.05$-44,580,000.00($0.29)-6.14

Athersys has lower revenue, but higher earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ImmunoGen and Athersys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
AthersysN/A-176.56%-112.67%

Institutional & Insider Ownership

73.0% of ImmunoGen shares are owned by institutional investors. Comparatively, 27.9% of Athersys shares are owned by institutional investors. 3.8% of ImmunoGen shares are owned by company insiders. Comparatively, 12.6% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Athersys beats ImmunoGen on 8 of the 13 factors compared between the two stocks.

Aclaris Therapeutics (NASDAQ:ACRS) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Aclaris Therapeutics and Athersys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aclaris Therapeutics-941.07%-104.00%-64.47%
AthersysN/A-176.56%-112.67%

Institutional & Insider Ownership

59.1% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Athersys shares are owned by institutional investors. 8.2% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Aclaris Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Athersys has a beta of -1.54, indicating that its share price is 254% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Aclaris Therapeutics and Athersys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aclaris Therapeutics0000N/A
Athersys00403.00

Athersys has a consensus target price of $9.00, indicating a potential upside of 405.62%. Given Athersys' higher possible upside, analysts plainly believe Athersys is more favorable than Aclaris Therapeutics.

Valuation & Earnings

This table compares Aclaris Therapeutics and Athersys' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclaris Therapeutics$4.23 million354.67$-161,350,000.00($2.25)-12.87
Athersys$5.63 million68.05$-44,580,000.00($0.29)-6.14

Athersys has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Summary

Athersys beats Aclaris Therapeutics on 8 of the 13 factors compared between the two stocks.

Antibe Therapeutics (NASDAQ:ATBPD) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Profitability

This table compares Antibe Therapeutics and Athersys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe Therapeutics-273.96%-176.23%-106.91%
AthersysN/A-176.56%-112.67%

Institutional and Insider Ownership

27.9% of Athersys shares are held by institutional investors. 12.6% of Athersys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Antibe Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Athersys has a beta of -1.54, indicating that its stock price is 254% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Antibe Therapeutics and Athersys, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics0000N/A
Athersys00403.00

Athersys has a consensus target price of $9.00, indicating a potential upside of 405.62%. Given Athersys' higher possible upside, analysts clearly believe Athersys is more favorable than Antibe Therapeutics.

Valuation and Earnings

This table compares Antibe Therapeutics and Athersys' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe Therapeutics$7.51 million161.29$-14,540,000.00($0.50)-6.26
Athersys$5.63 million68.05$-44,580,000.00($0.29)-6.14

Antibe Therapeutics has higher revenue and earnings than Athersys. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Summary

Athersys beats Antibe Therapeutics on 7 of the 13 factors compared between the two stocks.


Athersys Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
Gap Down
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.13-1.9%$1.50 billion$7.51 million-5.22
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77High Trading Volume
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.58-0.5%$1.16 billion$230,000.00-12.36
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38-8.0%$1.15 billionN/A-8.88High Trading Volume
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.54-1.6%$1.14 billionN/A0.00Lockup Expiration
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$30.78-0.7%$1.14 billionN/A0.00
Omeros logo
OMER
Omeros
1.4$18.23-2.9%$1.13 billion$111.81 million-7.66
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81-1.8%$1.09 billion$42.12 million-11.71Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50-1.4%$1.08 billionN/A-8.30
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42-7.3%$1.07 billion$120,000.00-3.86
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57-1.3%$1.07 billionN/A-8.82Analyst Report
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16-2.8%$1.07 billion$1.52 million-11.79
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.27-1.9%$1.07 billionN/A-7.00
NKTX
Nkarta
1.8$32.28-1.6%$1.06 billionN/A0.00News Coverage
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54-0.1%$992.72 million$800.40 million23.15
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75-1.1%$983.39 million$122.47 million-26.79
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00-1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76-1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37-0.2%$958.34 millionN/A-26.27News Coverage
Annexon logo
ANNX
Annexon
1.9$24.93-0.9%$951.28 millionN/A0.00
Humanigen logo
HGEN
Humanigen
1.6$17.25-1.9%$922.56 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$19.49-2.0%$913.96 million$173.32 million-7.99
Prothena logo
PRTA
Prothena
2.3$22.78-3.1%$911.34 million$810,000.00-8.90
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.